

Issued by JPAC: 30 October 2017

Implementation: To be determined by each Service

## Change Notification UK National Blood Services No. 22 - 2017

# Radiation Therapy

These changes apply to the individual Tissue and Cells Donor Selection Guidelines as stated below.

### 1. Bone Marrow and Peripheral Blood Stem Cell Donor Selection Guidelines for Unrelated Donors and Cord Blood Donor Selection Guidelines

Please modify "Discretionary", "See if Relevant", "Additional Information" and "Reason for Change" as follows:

#### Discretionary

- a) If fully recovered and is acceptable according to immunosuppression advice, accept.
- b) If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow up and is eligible under the Malignancy Guideline, accept.

#### See if Relevant

[Basal Cell Carcinoma](#)  
[Malignancy](#)  
[Immunosuppression](#)

#### Additional Information

Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a 'Designated Medical Officer' is required.

#### Reason for Change

Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.

\Continued

## 2. Tissue Donor Selection Guidelines – Live Donors

Please modify “Discretionary”, “See if Relevant”, “Additional Information” and “Reason for Change” as follows:

<b>Discretionary</b>	<p>a) If fully recovered and is acceptable according to immunosuppression advice, accept.</p> <p>b) If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow up and is eligible under the Malignancy Guideline, accept.</p>
<b>See if Relevant</b>	<p><a href="#">Basal Cell Carcinoma</a> <a href="#">Malignancy</a> <a href="#">Immunosuppression</a></p>
<b>Additional Information</b>	<p>Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a 'Designated Medical Officer' is required.</p>
<b>Reason for Change</b>	<p>Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.</p>

## 3. Tissue Donor Selection Guidelines – Deceased Donors

Please modify “Discretionary”, “See if Relevant”, “Additional Information” and “Reason for Change” as follows:

<b>Discretionary</b>	<p>a) <b>Eyes:</b> If related to malignancy and the eyes were not included in the field of irradiation, see Malignancy.</p> <p>b) If fully recovered and is acceptable according to immunosuppression advice, accept.</p> <p>c) If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow up and is eligible under the Malignancy Guideline, accept.</p>
----------------------	---

\Continued

**See if Relevant**


[Basal Cell Carcinoma](#)  
[Malignancy](#)  
[Immunosuppression](#)

**Additional Information**

Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a 'Designated Medical Officer' is required.

**Reason for Change**

Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.



**Dr Sheila MacLennan**  
**Professional Director - Joint UKBTS Professional Advisory Committee**  
☎ Direct Dial: (0113) 820 8638    ✉ [sheila.maclennan@nhsbt.nhs.uk](mailto:sheila.maclennan@nhsbt.nhs.uk)